Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7778138 | 0.95 | HPGD (0.74) | L3MBTL1HPGDGAALMNAKDM4E | |
| SCHEMBL17589255 | 0.93 | HPGD (0.72) | L3MBTL1HPGDGAALMNAKDM4E | |
| SCHEMBL8744900 | 0.89 | HPGD (0.81) | L3MBTL1HPGDGAALMNAKDM4E | |
| SCHEMBL3681101 | 0.89 | CNR2 (0.68) | L3MBTL1HPGDGAALMNAKDM4E | |
| SCHEMBL9829299 | 0.86 | LMNA (0.77) | L3MBTL1HPGDGAALMNAKDM4E | |
| SCHEMBL6290032 | 0.86 | L3MBTL1 (0.72) | L3MBTL1HPGDGAALMNAKDM4E | |
| SCHEMBL2186352 | 0.85 | HDAC2 (0.72) | L3MBTL1HPGDGAALMNAKDM4E | |
| SCHEMBL999773 | 0.85 | L3MBTL1 (0.70) | L3MBTL1HPGDGAALMNAKDM4E | |
| SCHEMBL4636200 | 0.85 | L3MBTL1 (0.70) | L3MBTL1HPGDGAALMNAKDM4E | |
| SCHEMBL5611877 | 0.85 | L3MBTL1 (0.70) | L3MBTL1HPGDGAALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | ALLEN DARIN ARTHUR (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030225036-A1 | Non-amidine containing protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1265897-A1 | NON-AMIDINE CONTAINING PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1242366-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1140859-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001070743-A1 | NON-AMIDINE CONTAINING PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001044172-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000035886-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | TFPI, HABP2, PLAT | L3MBTL1 2707/4885HPGD 894/4885GAA 906/4885 |
| US-20030225036-A1 | Non-amidine containing protease inhibitors | TFPI, SERPINE1, HABP2 | L3MBTL1 3163/4885HPGD 568/4885GAA 1891/4885 |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | TFPI, SERPINE1, HABP2 | L3MBTL1 2621/4885HPGD 966/4885GAA 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.